• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MR angio agent begins Phase II trials

Article

Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have

Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have been encouraging, according to the company. Code 7228, a proprietary coated iron oxide compound, is being groomed for cardiovascular applications.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.